Skip to content

Zevra Therapeutics, Inc. ZVRA Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$124.22M+235%$83.23M+179%$35.33M+139%$2.64M+104%-$91.99M-86.0%
$2.77M-57.2%$4.05M-36.5%$5.34M-3.4%$6.57M+65.2%$6.48M+160%
$12.62M-20.6%$12.63M-15.2%$12.37M+0.1%$15.73M+107%$15.9M+123%
-$46.21M+17.6%-$61.72M-35.2%
$802K+710%$866K$866K+1,103%$312K+27.9%$99K-62.9%
-$14.35M-$26.41M
$60.09M$0
-$42.35M-151%$12.06M-85.3%$10.31M-88.1%$68.55M+43.4%$82.5M+147%
$58.26M+1,157%$28.62M+409%$400K-96.3%$8.45M+131%-$5.51M-306%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Zevra Therapeutics, Inc. generate?
Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
What is Zevra Therapeutics, Inc.'s free cash flow?
After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
Where does Zevra Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.